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Research
Cadmium is a widespread toxic and carcino-
genic metal (Agency for Toxic Substances and 
Disease Registry 1999; Verougstraete et al. 
2003). In occupational studies, cadmium 
exposure has been associated with increased 
all-cause and cancer mortality, including 
lung, prostate, and renal cancer (Ades and 
Kazantzis 1988; Elinder et al. 1985; Pesch 
et al. 2000; Sorahan 1987). Population-based 
studies conducted in heavily polluted areas 
have linked cadmium to an increased risk of 
cancer, cardiovascular, and all-cause mortal-
ity (Arisawa et al. 2001; Nawrot et al. 2006; 
Nishijo et al. 1999, 2006). However, par-
ticipants in these studies were exposed to rela-
tively high levels of cadmium. The effects of 
cadmium exposure on mortality are not well 
characterized in general populations exposed 
to lower levels.
Environmental exposure to cadmium 
occurs primarily through smoking and the 
consumption of contaminated food and water 
(Satarug and Moore 2004; Verougstraete 
et al. 2003). Other sources include inhalation 
of contaminated air, particularly near specific 
point sources such as smelters and incinera-
tors (Satarug et al. 2003). Cadmium accumu-
lates in target tissues, especially in the renal 
cortex. The whole-body half-life for cadmium 
is estimated to be between 15 and 30 years 
(Bernard 2004; Satarug and Moore 2004).
The purpose of the present analysis was to 
evaluate the association of creatinine-corrected 
urinary cadmium with all-cause and cause-
specific mortality in the general U.S. popu-
lation using follow-up data from the Third 
National Health and Nutrition Examination 
Survey (NHANES III) Mortality Study. 
Urinary cadmium reflects cadmium concen-
trations in the kidneys, and it is considered 
the biomarker of choice to assess chronic 
exposure (Bernard 2004; Kjellstrom and 
Nordberg 1978).
Materials and Methods
Study population. NHANES III was a strati-
fied, multistage probability survey designed 
to select a representative sample of the civil-
ian noninstitutionalized U.S. population 
(National Center for Health Statistics 1994). 
Overall, 18,629 adults ≥ 20 years of age com-
pleted the NHANES III interview and exami-
nation between 1988 and 1994. We excluded 
2,577 participants missing data for urinary 
cadmium, 105 participants missing data for 
urinary creatinine, 382 participants miss-
ing data for smoking history, 1,593 partici-
pants missing data for other covariates, and 
14 who did not have follow-up information. 
After these exclusions, we included a total 
of 13,958 NHANES III participants in the 
present analyses. Participants we excluded due 
to missing data were older and more likely to 
be non-Hispanic black or Mexican American 
and to have a history of cardiovascular disease. 
However, those we excluded from the present 
study did not differ from those included in 
sex, smoking, or history of cancer. The pro-
tocol for NHANES III was approved by the 
National Center for Health Statistics of the 
Centers for Disease Control and Prevention 
Institutional Review Board. All participants 
gave written informed consent.
Baseline data collection. NHANES III 
baseline data were collected during an in-
home interview and a subsequent visit to a 
mobile examination center (National Center 
for Health Statistics 1994). During the in-
home interview, demographic and health-
related information was collected using a 
standardized questionnaire. We classified 
participants into one of three groups based 
on cigarette smoking: never smokers, former 
smokers, and current smokers. Smokers, both 
current and former, were also categorized into 
tertiles of pack-years smoked. Participants 
were considered to live in either a rural or 
an urban county based on U.S. Department 
of Agriculture rural–urban codes (National 
Center for Health Statistics 1994).
Height and weight were measured and 
body mass index (BMI) was calculated as 
weight in kilograms divided by height in 
meters squared. Blood pressure was measured 
three times during the in-home interview and 
three additional times during the participant’s 
visit to the mobile examination center. We 
averaged all blood pressure measurements for 
each participant and defined hypertension as 
systolic blood pressure ≥ 140 mmHg, diastolic 
blood pressure ≥ 90 mmHg, and/or current 
use of medication to lower blood pressure.
Serum C-reactive protein (CRP) was 
quantified using latex-enhanced nephelom-
etry, a low-sensitivity assay. We classified par-
ticipants as having CRP < 0.3 mg/dL (i.e., 
below the limit of detection), between 0.3 
and 0.9 mg/dL, or ≥ 1.0 mg/dL. Plasma 
glucose was measured using an enzymatic 
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Ba c k g r o u n d: Cadmium exposure has been associated with increased all-cause, cancer, and cardio-
vascular disease mortality. However, studies investigating this association have included participants 
with considerably higher levels of cadmium than those found in the general population.
oB j e c t i v e: We aimed to evaluate the association of creatinine-corrected urinary cadmium levels 
with all-cause and cause-specific mortality in the U.S. general population.
Me t h o d s : We analyzed the relationship between cadmium measured in 13,958 adults who partici-
pated in the Third National Health and Nutrition Examination Survey in 1988–1994 and were fol-
lowed through 31 December 2000, and all-cause, cancer, cardiovascular disease, and coronary heart 
disease mortality.
re s u l t s: The geometric mean levels of urinary cadmium per gram of urinary creatinine in study 
participants were 0.28 and 0.40 µg/g for men and women, respectively (p < 0.001). After multi-
variable adjustment, including smoking, a major source of cadmium exposure in nonoccupationally 
exposed populations, the hazard ratios [95% confidence interval (CI)] for all-cause, cancer, cardio-
vascular disease, and coronary heart disease mortality associated with a 2-fold higher creatinine-cor-
rected urinary cadmium were, respectively, 1.28 (95% CI, 1.15–1.43), 1.55 (95% CI, 1.21–1.98), 
1.21 (95% CI, 1.07–1.36), and 1.36 (95% CI, 1.11–1.66) for men and 1.06 (95% CI, 0.96–1.16), 
1.07 (95% CI, 0.85–1.35), 0.93 (95% CI, 0.84–1.04), and 0.82 (95% CI, 0.76–0.89) for women.
co n c l u s i o n s: Environmental cadmium exposure was associated with an increased risk of all-cause, 
cancer, and cardiovascular disease mortality among men, but not among women. Additional efforts 
are warranted to fully explain gender differences on the impact of environmental cadmium exposure.
key w o r d s : cadmium exposure, cancer, cardiovascular disease, epidemiology, human, mortality, 
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reaction. We defined diabetes mellitus as fast-
ing plasma glucose ≥ 126 mg/dL, non  fasting 
plasma glucose ≥ 200 mg/dL, and/or a self-
reported history of diabetes with concurrent 
use of antidiabetes medication. Total serum 
cholesterol was measured enzymatically. 
Serum creatinine was measured by a kinetic 
rate Jaffe method. We calculated estimated 
glomerular filtration rate (eGFR) using the 
Modification of Diet and Renal Disease equa-
tion after aligning the serum creatinine con-
centrations with the assay employed in the 
development of the equation (Coresh et al. 
2002; Levey et al. 1999). We classified indi-
viduals as having an eGFR of ≥ 90, 60–89, or 
< 60 mL/min/1.73 m2.
A detailed description of the measure-
ment of urinary cadmium levels is available 
elsewhere (Gunter et al. 1996). In brief, all 
materials used for collecting and processing 
urinary cadmium specimens were screened 
for possible cadmium contamination. A spot 
urine specimen was collected and shipped 
at –20°C to the NHANES laboratory at the 
Centers for Environmental Health at the 
Centers for Disease Control and Prevention 
in Atlanta, Georgia (USA). Urinary cadmium 
was measured by graphite furnace atomic 
absorption with Zeeman background correc-
tion using the Centers for Disease Control 
and Prevention modification (Gunter et al. 
1996) of the method of Pruszkowska et al. 
(1983). Specimens were analyzed in duplicate, 
and the average of the two measurements was 
reported. The detection limit was 0.03 µg/L.
The analytical laboratory followed exten-
sive quality control procedures (Gunter et al. 
1996). The National Institute of Standards 
and Technology standard reference material 
Toxic Elements in Freeze-Dried Urine (SRM 
2670) was used for external calibration, with 
excellent agreement over the duration of the 
survey (Paschal et al. 2000). The interassay 
coefficients of variation ranged from 2.8% 
to 13.6%. Additionally, in an external qual-
ity assurance program from the Center of 
Toxicology of Quebec, laboratory measures 
were within 10% of reference means for 
urinary cadmium (r2 = 0.97) (Paschal et al. 
2000).
Because NHANES III collected only spot 
urine samples, we performed all analyses using 
creatinine-corrected urinary cadmium values 
(urinary cadmium divided by urinary creati-
nine concentrations, expressed as micrograms 
per gram) to account for between-participant 
differences in urine dilution. Urinary crea-
tinine was measured using the Jaffe method 
with a Beckman ASTRA automated analyzer 
(Paschal et al. 2000).
Mortality follow-up. Adult NHANES 
III participants were followed for mortality 
through 31 December 2000. Matching was 
used to link NHANES III participants with 
the National Death Index to ascertain vital 
status and cause of death (National Center 
for Health Statistics 2006). Matching was 
based on 12 identifiers for each participant 
(e.g., Social Security number, sex, date of 
birth). A total of 1,690 eligible participants 
was identified as deceased over follow-up. 
Identical matching methodology applied to 
the NHANES I Epidemiological Follow-up 
Study (National Center for Health Statistics 
2006) for validation purposes found that 
96.1% of deceased participants and 99.4% of 
living participants were correctly classified.
We calculated follow-up for each 
study participant as the time between their 
NHANES III examination and the date of 
death, the date they reached 90 years of age, 
or 31 December 2000, whichever occurred 
first. We censored follow-up at 90 years of age 
because mortality was very high after this age 
and few participants contributed person-time 
experience in this age category. The mean 
follow-up time among participants who were 
alive at the end of follow-up and among par-
ticipants who died was 9.0 years and 5.1 years, 
respectively.
In the NHANES III Mortality Study, 
cause of death was determined using the 
underlying cause listed on death certifi-
cates. The International Classification of 
Diseases, 9th Revision [ICD-9; World Health 
Organization (WHO) 1975], was used for 
deaths occurring between 1988 and 1998 
and ICD-10 (WHO 1993) for deaths during 
1999 and 2000. Cause-specific mortality was 
ascertained for cancer (ICD-9 codes 140–208, 
ICD-10 codes C00–C97), cardiovascular dis-
ease (ICD-9 codes 390–434 and 436–459, 
ICD-10 codes I00–I99), and coronary heart 
disease (ICD-9 codes 410–414 and 429.2, 
ICD-10 codes I20–I25).
Statistical methods. Creatinine-corrected 
urinary cadmium levels were substantially dif-
ferent for men and women; moreover, we 
observed significant differences by sex in 
the association of cadmium with mortality. 
Therefore, we conducted all analyses sepa-
rately for men and women. We categorized 
creatinine-corrected urinary cadmium levels 
in tertiles according to sex-specific cut points. 
We calculated baseline levels of study covari-
ates for each tertile of creatinine-corrected 
urinary cadmium after adjusting for age 
(restricted quadratic spline with knots at the 
10th, 50th, and 90th percentile of the over-
all study sample) and race/ethnicity (non-
Hispanic white, non-Hispanic black, Mexican 
American, other) using linear regression for 
continuous covariates and logistic regression 
for dichotomous covariates.
For risk analyses, we used Cox regression 
to estimate the hazard ratios and 95% con-
fidence intervals (CIs) for mortality associ-
ated with each tertile of creatinine-corrected 
urinary cadmium compared with the lowest 
tertile. We computed tests for linear trend 
across tertiles of creatinine-corrected urinary 
cadmium by including the median of each 
tertile as a continuous variable in the Cox 
regression models. Further analyses included 
creatinine-corrected urinary cadmium as a 
continuous, log-transformed variable. For 
these analyses, we present the hazard ratios for 
mortality end points associated with a 2-fold 
increase in creatinine-corrected urinary cad-
mium, which corresponds approximately to 
the difference between the 75th and the 50th 
percentiles of the creatinine-corrected uri-
nary cadmium distribution in both males and 
females. We further evaluated the creatinine-
corrected urinary cadmium–mortality rela-
tionships using restricted quadratic splines 
with knots at 0.086 µg/g, 0.378 µg/g, and 
1.23 µg/g (corresponding to the 10th, 50th, 
and 90th percentiles of the creatinine-cor-
rected urinary cadmium distribution in the 
overall study sample).
Cox models included adjustment for 
age (restricted quadratic spline with knots 
at the 10th, 50th, and 90th percentile of 
the overall study sample), race/ethnicity 
(non-Hispanic white, non-Hispanic black, 
Mexican American, other), menopausal 
status for women, urban residence (urban, 
rural), cigarette smoking category (never, for-
mer, current), tertile of pack-years smoked 
(< 9.0, 9.0–28.2, ≥ 28.3), alcohol consump-
tion (< 12, ≥ 12 drinks in the past year), high 
school education, physical activity (none, 1–2, 
≥ 3 times a week), annual household income 
(< $20,000, ≥ $20,000), BMI (continuous), 
CRP (not detectable, 0.3–0.9, ≥ 1.0 mg/dL), 
total cholesterol (continuous), diabetes mel-
litus, systolic blood pressure (continuous), use 
of antihypertensive medication, and category 
of eGFR (< 60, 60–89, ≥ 90 mL/min/1.73 
m2). We tested for statistical interaction by 
including the product of creatinine-corrected 
urinary cadmium (log-transformed continu-
ous) and each covariate in the Cox regression 
models. We conducted five separate sensitiv-
ity analyses a) excluding participants with a 
history of cardiovascular disease and/or cancer 
at baseline, b) adjusting for cotinine instead 
of pack-years smoked, c) adjusting for poverty 
index ratio as an alternative proxy for socio-
economic status (n = 12,930 with available 
data for poverty income ratio), d) adjusting 
for urinary creatinine in the Cox regression 
model instead of dividing cadmium concen-
trations by creatinine, and e) excluding par-
ticipants with urinary creatinine ≥ 300 mg/
dL. Results were qualitatively unchanged for 
each of these analyses (data not shown).
We analyzed data using SUDAAN (ver-
sion 9.0; Research Triangle Institute, Research 
Triangle Park, NC, USA) to account for 
the complex NHANES sampling design, Menke et al.
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including unequal probabilities of selection, 
oversampling, and nonresponse.
Results
The geometric mean creatinine-corrected uri-
nary cadmium level was 0.28 µg/g in men and 
0.40 µg/g in women (p < 0.001). Creatinine-
corrected urinary cadmium levels were associ-
ated with age and with cigarette smoking in 
both men and women (Table 1). Higher cre-
atinine-corrected urinary cadmium levels were 
also associated with a lower BMI, less than 
a high school education, no regular physi-
cal activity, household income < $20,000, a 
higher prevalence of CRP ≥ 1.0 mg/dL, and 
higher blood lead concentrations among men 
and women.
Cadmium and mortality among men. The 
number of deaths due to all causes, cancer, 
cardiovascular disease, and coronary heart dis-
ease among men were 1,001, 266, 449, and 
241, respectively. Among men, creatinine-
corrected urinary cadmium levels were posi-
tively associated with increased mortality. The 
  multivariable-adjusted hazard ratios for all-cause, 
cancer, cardiovascular, and coronary heart dis-
ease mortality for the highest compared with the 
lowest tertile were 1.68 (95% CI, 1.09–2.58), 
4.29 (95% CI, 2.31–7.96), 1.33 (95% CI, 
0.69–2.56), and 2.48 (95% CI, 0.85–7.27), 
respectively (Table 2). Because of few cancer 
deaths in the lowest tertile of creatinine-corrected 
urinary cadmium (n = 15), the hazard ratio esti-
mates for cancer mortality comparing the upper 
tertiles to the lowest tertile may be unstable, 
although the two upper tertiles still showed a 
graded, positive association. The multivariable-
adjusted hazard ratios for all-cause, cancer, and 
cardiovascular mortality associated with a 2-fold 
increase in creatinine-corrected urinary cadmium 
were 1.28 (95% CI, 1.15–1.43), 1.55 (95% CI, 
1.21–1.98), and 1.21 (95% CI, 1.07–1.36), 
respectively (Figure 1). The analogous hazard 
ratio for coronary heart disease mortality was 
1.36 (95% CI, 1.11–1.66). In spline regression 
models, the relative hazard for all-cause, cancer, 
and cardiovascular mortality in men increased 
throughout the range of creatinine-corrected 
urinary cadmium (Figure 2).
The association of creatinine-corrected 
urinary cadmium and mortality end points 
Table 1. Baseline characteristicsa of study participants by sex and tertile of creatinine-corrected urinary cadmium.
  Men  Women
  < 0.21 µg/g  0.21–0.47 µg/g  ≥ 0.48 µg/g  p-Value  < 0.29 µg/g  0.29–0.67 µg/g  ≥ 0.68 µg/g  p-Value
Characteristic  (n = 1,867)  (n = 2,173)  (n = 2,518)  for trend  (n = 2,115)  (n = 2,697)  (n = 2,586)  for trend
Age (years)  33.8 (0.6)  43.7 (0.6)  53.4 (0.4)  < 0.001  34.6 (0.4)  45.5 (0.7)  55.1 (0.7)  < 0.001
Non-Hispanic white (%)  83.1 (1.3)  75.0 (2.2)  74.6 (2.0)  0.005  81.5 (1.8)  75.1 (1.4)  73.2 (1.8)  0.007
Non-Hispanic black (%)  7.2 (0.6)  10.4 (0.7)  11.0 (0.9)  0.001  8.6 (0.9)  13.6 (1.0)  10.8 (1.1)  0.39
Mexican-American (%)  5.2 (0.5)  5.6 (0.6)  5.2 (0.5)  0.90  3.9 (0.4)  5.4 (0.5)  4.9 (0.4)  0.13
Postmenopausal status (%)  —  —  —  —  37.8 (1.6)  39.4 (1.5)  43.1 (1.6)  < 0.001
Urban residence (%)  52.6 (5.1)  51.3 (5.2)  42.7 (5.0)  0.01  48.3 (5.2)  48.0 (4.9)  46.5 (4.9)  0.52
Systolic blood pressure (mmHg)  124.7 (0.5)  124.2 (0.6)  125.1 (0.5)  0.32  120.5 (0.6)  120.2 (0.7)  119.6 (0.7)  0.29
Diabetes (%)  7.0 (1.4)  5.2 (0.6)  5.5 (0.4)  0.49  4.9 (0.9)  5.4 (0.8)  5.0 (0.4)  0.73
BMI (kg/m2)  27.1 (0.2)  27.0 (0.2)  26.0 (0.2)  < 0.001  26.4 (0.2)  27.1 (0.2)  26.0 (0.2)  0.006
Current smoker (%)  11.9 (1.1)  28.5 (1.1)  65.2 (1.6)  < 0.001  11.2 (0.9)  23.2 (1.3)  48.4 (2.0)  < 0.001
Pack-years ≥ 28 (%)b  3.6 (0.8)  13.3 (1.4)  43.6 (1.9)  < 0.001  1.7 (0.4)  5.4 (0.7)  24.2 (1.1)  < 0.001
eGFR < 60 mL/min/1.73 m2 (%)  4.5 (1.1)  3.7 (0.5)  3.5 (0.3)  0.25  4.6 (0.9)  6.2 (0.6)  4.6 (0.6)  0.16
High school education (%)  85.4 (1.5)  74.3 (1.6)  64.6 (1.9)  < 0.001  82.7 (1.4)  77.5 (1.4)  72.0 (1.5)  < 0.001
Consume alcohol (%)  67.9 (2.0)  65.9 (2.5)  67.9 (2.2)  0.74  43.5 (2.1)  45.0 (1.8)  42.5 (2.1)  0.44
No regular physical activity (%)  38.9 (1.6)  42.3 (2.1)  51.9 (1.5)  < 0.001  49.6 (2.8)  53.5 (1.3)  58.1 (2.1)  0.002
Household income < $20,000 (%)  21.6 (1.4)  26.8 (1.6)  39.6 (2.0)  < 0.001  29.7 (1.9)  34.9 (1.6)  41.2 (1.8)  < 0.001
CRP ≥ 1.0 mg/dL (%)  2.6 (0.6)  3.4 (0.5)  7.3 (1.0)  < 0.001  7.6 (0.7)  8.8 (1.0)  13.5 (1.1)  < 0.001
Total cholesterol (mg/dL)  199.9 (1.6)  201.9 (1.5)  204.3 (1.4)  0.05  208.9 (1.3)  205.0 (1.2)  204.1 (1.3)  0.01
Blood lead (µg/dL [geometric  2.81 (2.61–3.04)  3.50 (3.28–3.74)  4.65 (4.38–4.94)  < 0.001  1.73 (1.63–1.84)  2.07 (1.97–2.17)  2.62 (2.45–2.81)  < 0.001
  mean (95% CI)])
Values are means (SE) or percentages (SE) unless otherwise noted. 
aAll values except for age and race/ethnicity were standardized for age (restricted quadratic spline with knots at the 10th, 50th, and 90th percentile of the overall study sample) and race/
ethnicity (non-Hispanic white, non-Hispanic black, Mexican American, other). bThis level represents the highest tertile of pack-years. 
Table 2. Hazard ratio (95% CI) for all-cause, cancer, cardiovascular disease, and coronary heart disease mortality associated with sex and tertile of creatinine-
corrected urinary cadmium.
  Men  Women
   p-Value    p-Value
Mortality  < 0.21 µg/g  0.21–0.47 µg/g  ≥ 0.48 µg/g  for trend  < 0.29 µg/g  0.29–0.67 µg/g  ≥ 0.68 µg/g  for trend
All-cause  n = 94  n = 250  n = 657    n = 71  n = 205  n = 413 
 Age and race/ethnicity adjusted  1.00  1.54 (1.05–2.26)  2.48 (1.75–3.50)  < 0.001  1.00  1.32 (0.89–1.96)  1.66 (1.18–2.34)  0.005
 Multivariable adjusteda  1.00  1.43 (0.95–2.16)  1.68 (1.09–2.58)  0.02  1.00  1.18 (0.78–1.78)  1.14 (0.78–1.66)  0.87
Cancerb  n = 15  n = 47  n = 204    n = 15  n = 46  n = 112 
 Age and race/ethnicity adjusted  1.00  2.54 (1.35–4.80)  8.03 (4.58–14.1)  < 0.001  1.00  1.03 (0.51–2.08)  1.76 (0.88–3.50)  0.02
 Multivariable adjusteda  1.00  2.16 (1.11–4.21)  4.29 (2.31–7.96)  0.001  1.00  0.93 (0.47–1.86)  1.11 (0.55–2.22)  0.52
Cardiovascular disease  n = 44  n = 129  n = 276    n = 41  n = 103  n = 176 
 Age and race/ethnicity adjusted  1.00  1.75 (0.94–3.25)  1.89 (1.07–3.31)  0.03  1.00  1.06 (0.52–2.14)  1.05 (0.61–1.80)  0.92
 Multivariable adjusteda  1.00  1.66 (0.89–3.11)  1.33 (0.69–2.56)  0.68  1.00  0.96 (0.47–1.97)  0.82 (0.47–1.42)  0.19
Coronary heart disease  n = 21  n = 65  n = 155    n = 19  n = 36  n = 71 
 Age and race/ethnicity adjusted  1.00  2.58 (0.96–6.93)  2.58 (1.02–6.49)  0.15  1.00  0.56 (0.28–1.12)  0.69 (0.42–1.15)  0.81
 Multivariable adjusteda  1.00  2.69 (0.94–7.71)  2.48 (0.85–7.27)  0.42  1.00  0.49 (0.26–0.90)  0.45 (0.24–0.83)  0.08
n, number of events.
aAdjustment included age (restricted quadratic spline with knots at the 10th, 50th, and 90th percentile of the overall study sample), race/ethnicity (non-Hispanic white, non-Hispanic 
black, Mexican American, other), postmenopausal status (among women), urban residence (urban, rural), annual household income (< $20,000, ≥ $20,000), high school education, smok-
ing category (never, former who quit ≥ 4 years ago, former who quit < 4 years ago, current), tertile of pack-years (< 9.0, 9.0–28.2, ≥ 28.2), physical activity (none, 1–2, ≥ 3 times a week), 
diabetes, BMI (continuous), alcohol consumption (< 12, ≥ 12 drinks in the past year), CRP (not detectable, 0.3–0.9, ≥ 1.0 mg/dL), total cholesterol (continuous), systolic blood pressure 
(continuous), blood pressure–lowering medication, blood lead (log-transformed), and eGFR (< 60, 60–89, ≥ 90 mL/min, 1.73 m2). bBecause of few cancer (n = 15 for men and women) and 
coronary heart disease (n = 21 for men and n = 19 for women) deaths in the lowest tertile, the hazard ratio estimates for cancer and coronary heart disease mortality may be unstable.Cadmium and mortality
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was consistent across selected subgroups of 
men except for Mexican Americans (p-value 
for interaction < 0.05 for all-cause, cancer, 
and cardiovascular mortality) (Figure 1).
Cadmium and mortality among women. 
The numbers of deaths due to all causes, 
cancer, cardiovascular disease, and coronary 
heart disease among women were 689, 173, 
320, and 126, respectively. Among women, 
we found no association between creatinine-
  corrected urinary cadmium levels and mortal-
ity. The multivariable-adjusted hazard ratios 
for all-cause, cancer, cardiovascular, and coro-
nary heart disease mortality for the highest 
compared with the lowest tertile were 1.14 
(95% CI, 0.78–1.66), 1.11 (95% CI, 0.55–
2.22), 0.82 (95% CI, 0.47–1.42), and 0.45 
(95% CI, 0.24–0.83), respectively (Table 2). 
There are few cancer (n = 15) and coronary 
heart disease (n = 19) deaths in the lowest 
tertile of urinary creatinine-corrected urinary 
cadmium. Therefore, the hazard ratio esti-
mates for cancer and coronary heart disease 
mortality may be unstable. The multivariable-
adjusted hazard ratios for all-cause, cancer, 
and cardiovascular mortality associated with a 
2-fold increase in creatinine-corrected urinary 
cadmium were 1.06 (95% CI, 0.96–1.16), 
1.07 (95% CI, 0.85–1.35), and 0.93 (95% 
CI, 0.84–1.04), respectively (Figure 3). The 
analogous hazard ratio for coronary heart dis-
ease mortality was 0.82 (95% CI, 0.76–0.89). 
In spline regression models, we found no evi-
dence of increased mortality with increasing 
creatinine-corrected urinary cadmium levels 
in women (Figure 4).
There were significant interactions of crea-
tinine-corrected urinary cadmium and meno-
pause status for all-cause and cancer mortality 
outcomes (p-values for interaction < 0.05), with 
higher hazard ratios among women who were 
postmenopausal than premenopausal (Figure 
3). Additionally, creatinine-corrected urinary 
cadmium was positively associated with all-
cause mortality among women with BMI < 25 
kg/m2 (p-value interaction < 0.05) and with 
cancer mortality among non-Hispanic blacks, 
current smokers, and women with an annual 
household income < $20,000 (p-values for 
interaction < 0.05).
Discussion
In this large, population-based prospective 
study, higher creatinine-corrected urinary 
cadmium levels were associated with increased 
all-cause, cancer, and cardiovascular disease 
Figure 1. Multivariable-adjusted hazard ratio (95% CI) for all-cause, cancer, and cardiovascular disease mortality associated with a 2-fold increase in creatinine-
corrected urinary cadmium overall, and by important subgroups among men. Adjustment included age (restricted quadratic spline with knots at the 10th, 50th, and 
90th percentile of the overall study sample), race/ethnicity (non-Hispanic white, non-Hispanic black, Mexican American, other), urban residence (urban, rural), 
annual household income (< $20,000, ≥ $20,000), high school education, smoking category (never, former who quit ≥ 4 years ago, former who quit < 4 years ago, 
current), tertile of pack-years (< 9.0, 9.0–28.2, ≥ 28.2), physical activity (none, 1–2, ≥ 3 times a week), diabetes, BMI (continuous), alcohol consumption (< 12, ≥ 12 
drinks in the past year), CRP (not detectable, 0.3–0.9, ≥ 1.0 mg/dL), total cholesterol (continuous), systolic blood pressure (continuous), blood pressure–lowering 
medication, blood lead (log-transformed), and eGFR (< 60, 60–89, ≥ 90 mL/min, 1.73 m2). A 2-fold increase in urinary cadmium corresponds approximately to the dif-
ference between the 75th and 50th percentiles of the cadmium distribution (0.61 µg/g and 0.32 µg/g, respectively). The sizes of the boxes are inversely related to 
the variance of the point estimate.
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Figure 2. Multivariable-adjusted relative hazard 
of all-cause, cardiovascular disease, and cancer 
mortality associated with creatinine-corrected uri-
nary cadmium using restricted quadratic splines 
among men (adjusted as listed for Figure 1).
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mortality among men. This increased mortal-
ity was present among current, former, and 
never-smoking men, despite the differences in 
creatinine-corrected urinary cadmium levels 
among these three groups (geometric means 
of 0.42, 0.38, and 0.16 µg/g, respectively). 
Creatinine-corrected urinary cadmium was 
not associated with increased mortality among 
women overall, even though women had 
higher creatinine-corrected urinary cadmium 
levels than did men.
Our finding of higher creatinine-corrected 
urinary cadmium levels in women is consis-
tent with previous studies showing a higher 
body burden of cadmium in women, regardless 
of the biomarker used (Nishijo et al. 2004). 
Furthermore, biopsy studies have demonstrated 
higher levels of kidney and liver cadmium in 
women compared with men (Benedetti et al. 
1999; Satarug et al. 2002). This difference exists 
even though men are thought to have greater 
dietary intake of cadmium than did women 
(Choudhury et al. 2001). The reason for a 
higher body burden of cadmium in women 
seems to be related to their higher cadmium 
absorption in the digestive track. Cadmium 
is absorbed in the duodenum by the divalent 
metal transporter DMT1 (divalent metal trans-
porter 1), the primary mechanism for uptake 
of nonheme iron that also has an affinity for 
cadmium (Nishijo et al. 2004). Iron deficiency 
up-regulates DMT1, increasing cadmium 
absorption. Therefore, women may absorb more 
cadmium through their digestive track than do 
men, on average, as a result of higher rates of 
iron deficiency (Vahter et al. 2007; Zacharski 
et al. 2000). Men and women may also differ 
in cadmium retention, regulated by metallothi-
onein (Klaassen et al. 1999; Nordberg 2004). 
Metallothionein levels and expression of the 
metallothionein IIA gene (MTIIA) are higher 
in women than in men (Kwon et al. 2007), 
which could explain higher levels of cadmium 
in women as well as potentially greater pro-
tection against toxicity. Additionally, urinary 
cadmium concentrations seem to be genetically 
determined to a greater extent in women com-
pared with men (Bjorkman et al. 2000).
Although higher cadmium levels in 
women point to sex differences in cadmium 
pharmaco  kinetics, it is unclear why cadmium 
was associated with mortality among men but 
not among all women in the present study. 
Few studies have presented mortality results for 
men and women separately. Among residents 
in a heavily polluted region of Japan (geometric 
mean creatinine-corrected urinary cadmium, 
4.6 µg/g for men and 7.2 µg/g for women), 
there was a positive dose–response association 
between creatinine-corrected urinary cadmium 
and all-cause mortality over 15 years of follow-
up among men and women (Nakagawa et al. 
2006). However, in a separate contaminated 
region of Japan (median creatinine-corrected 
urinary cadmium, 7.0 µg/g for men and 
12.1 µg/g for women), the hazard ratios for all-
cause mortality, comparing residents with cre-
atinine-corrected urinary cadmium ≥ 10 µg/g 
versus < 10 µg/g, were 1.83 (95% CI, 0.83–
4.03) and 0.82 (95% CI, 0.43–1.59) for men 
and women, respectively (Arisawa et al. 2001). 
However, in this latter study, elevated urine 
Figure 3. Multivariable-adjusted hazard ratio (95% CI) for all-cause, cancer, and cardiovascular disease mortality associated with a 2-fold increase in creatinine-
corrected urinary cadmium overall, and by important subgroups among women. Adjustment included age (restricted quadratic spline with knots at the 10th, 50th, 
and 90th percentile of the overall study sample), race/ethnicity (non-Hispanic white, non-Hispanic black, Mexican American, other), postmenopausal status, 
urban residence (urban, rural), annual household income (< $20,000, ≥ $20,000), high school education, smoking category (never, former who quit ≥ 4 years ago, 
former who quit < 4 years ago, current), tertile of pack-years (< 9.0, 9.0–28.2, ≥ 28.2), physical activity (none, 1–2, ≥ 3 times a week), diabetes, BMI (continuous), 
alcohol consumption (< 12/≥ 12 drinks in the past year), CRP (not detectable, 0.3–0.9, ≥ 1.0 mg/dL), total cholesterol (continuous), systolic blood pressure (continu-
ous), blood pressure lowering medication, blood lead (log-transformed), and eGFR (< 60, 60–89, ≥ 90 mL/min/1.73 m2). A 2-fold increase in urinary cadmium cor-
responds approximately to the difference between the 75th and 50th percentiles of the cadmium distribution (0.86 µg/g and 0.44 µg/g, respectively). The sizes of 
the boxes are inversely related to the variance of the point estimate.
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β2-microglobulin, a biomarker of cadmium-
induced renal tubular dysfunction, was associ-
ated with increased mortality among both men 
and women. Specifically, the hazard ratios for 
mortality comparing β2-microglobulin ≥ 1,000 
µg/g of creatinine versus < 1,000 µg/g were 
2.05 (95% CI, 0.94–4.47) and 2.05 (95% CI, 
1.05–4.01) for men and women, respectively. 
Indeed, previous studies investigating the asso-
ciation of biomarkers of cadmium-induced 
renal tubular dysfunction with increased risk of 
mortality have consistently found associations 
among both men and women (Arisawa et al. 
2001; Nishijo et al. 2006; Satarug et al. 2003).
Potential leads toward understanding the 
different association of cadmium and mor-
tality in men and women may be derived 
from our observation of statistical inter  action 
between cadmium and menopause status 
among women. This could result from a redis-
tribution of cadmium from bone after meno-
pause, which has been shown for lead (Nash 
et al. 2004). Cadmium is also stored in bone, 
although to a lesser extent than lead (Bocio 
et al. 2005). In addition, cadmium shows 
androgen- and estrogen-like activities in vitro 
and in vivo, with potential differential effects 
in premenopausal women, post  menopausal 
women, and men (Vahter et al. 2007). Further 
research is needed to confirm the heterogene-
ity of cadmium effects by sex and menopausal 
status at low levels of exposure and to identify 
the responsible mechanisms.
Cadmium and cadmium compounds are 
established carcinogens in humans (Agency 
for Toxic Substances and Disease Registry 
1999; International Agency for Research on 
Cancer 1993). In the present study, higher 
creatinine-corrected urinary cadmium lev-
els were associated with increased cancer 
mortality among men. This association per-
sisted after adjusting for smoking status and 
pack-years of smoking. Lifetime cumulative 
smoking may not have been fully captured 
by our adjustment variables, and we cannot 
rule out residual confounding by smoking 
as an explanation of our findings. However, 
the association between creatinine-corrected 
urinary cadmium and mortality was remark-
ably similar when restricted to never-smoking 
men, making residual confounding by smok-
ing less likely. It is important to note that 
the cadmium–cancer association may differ 
when investigating fatal cancer as opposed to 
all incident cancers. Our study included only 
cancer mortality, due largely to metastatic dis-
ease, a unique subset of all incident cancers.
Environmental exposure to cadmium has 
been found to be associated with cardiovas-
cular disease mortality (Inskip et al. 1982; 
Nishijo et al. 2006). Conversely, higher levels 
of urinary and blood cadmium were not asso-
ciated with prevalent cardiovascular disease 
in the CADMIBEL (Cadmium in Belgium) 
study (Staessen et al. 1991). One important 
difference between these studies is the distinc-
tion between cardiovascular disease mortality 
and all cardiovascular disease. Fatal cardio-
vascular disease is a unique subset of all inci-
dent cardiovascular disease. Therefore, the 
cadmium–cardiovascular disease association 
may differ when investigating all incident car-
diovascular disease.
Cadmium may induce cardiovascular dis-
ease via renal damage (Bernard 2004; Satarug 
et al. 2006). Among 3,178 Japanese men and 
women, cadmium-induced renal tubular dys-
function was associated with a significantly 
increased risk of mortality due to heart fail-
ure, stroke, and kidney disease, with similar 
findings for men and women (Nishijo et al. 
2006). The importance of cadmium-induced 
kidney damage in the U.S. general popula-
tion, however, is uncertain, because signs of 
tubular damage are typically not detected until 
urinary cadmium concentrations are as high 
as 1.7 µg/g (Satarug et al. 2003). However, 
cadmium levels were associated with periph-
eral artery disease in the U.S. general popula-
tion in NHANES 1999–2000 (Navas-Acien 
et al. 2004, 2005), suggesting that cadmium 
may play a role in the atherosclerotic pro-
cess. Conversely, several studies conducted in 
Belgium investigating the association of uri-
nary and blood cadmium with blood pressure 
found no indication that cadmium increases 
blood pressure among men or women 
(Staessen et al. 1984, 1988, 1991, 2000).
In addition to potential residual confound-
ing by smoking, other limitations of our study 
include measurement error due to within-
person variability in cadmium and creatinine 
excretion in single spot urine samples, and the 
limited study power to evaluate some causes 
of mortality. Also, in NHANES III, causes of 
death were assigned based on death certificates, 
which may contain inaccurate information and 
may not be generalizable to nonfatal events.
Despite these limitations, the present 
study has a number of strengths. NHANES 
III collected data on a variety of health expo-
sures and outcomes using a rigorous proto-
col with extensive quality control procedures. 
NHANES III findings are generalizable to 
the U.S. noninstitutionalized civilian popula-
tion (National Center for Health Statistics 
1994). Finally, the large sample size allowed 
the investigation between creatinine-corrected 
urinary cadmium and mortality in key sub-
groups, after adjustment for important con-
founders, and after exclusion of participants 
with a history of cardiovascular disease or can-
cer at baseline.
In summary, increased creatinine-cor-
rected urinary cadmium levels were associated 
with an increased risk of all-cause, cancer, 
and cardiovascular disease mortality among 
men in the U.S. general population. This 
association was present among most sub-
groups investigated, including non-Hispanic 
white and non-Hispanic black men, but not 
Mexican-American men. Furthermore, the 
association was present among men who 
reported never smoking, a group with rela-
tively low levels of creatinine-corrected uri-
nary cadmium. In contrast, higher levels of 
creatinine-corrected urinary cadmium were 
not associated with mortality among women. 
The potential public health implications of 
these findings are substantial, because expo-
sure to low levels of cadmium is widespread. 
Future studies should be conducted to fully 
characterize the public health impact of envi-
ronmental cadmium exposure and to explain 
the differences in cadmium-related mortality 
between men and women.
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